Vertex and CRISPR Therapeutics Report Real-World Outcomes for Casgevy in Sickle Cell Disease

Vertex Pharmaceuticals and CRISPR Therapeutics today presented real-world outcomes data for Casgevy (exagamglogene autotemcel) in patients with sickle cell disease treated in clinical practice. The data showed that all patients who received Casgevy achieved transfusion independence and elimination of vaso-occlusive crises, consistent with clinical trial results. These real-world data confirm the transformative potential of Casgevy gene therapy.